Skip to content

OS Therapies OSTX Net Change in Cash

Net Change in Cash at other companies

Immunome logo
ImmunomeIMNM
-$70.79M-162%
CTO
Citius Oncology, Inc.CTOR
-$4.66M-575%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$9.21M+197%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$21M-150%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$117.04M+241%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
-$2.78M-101%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's net change in cash?
OS Therapies (OSTX) reported net change in cash of $647.72K in Q1 2026.
How has OS Therapies's net change in cash changed year-over-year?
OS Therapies's net change in cash increased by 125.3% year-over-year, from -$2.56M to $647.72K.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.